This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: AGN AOS COG ETFC LLY

GlaxoSmithKline (GSK) was upgraded at Argus to buy from hold. Asset swap with Novartis is attractive, Argus said.

Illumina (ILMN) was upgraded at Maxim Group to buy from hold. Twelve-month price target is $205. Clinical customers are accelerating adoption and the company is seeing better penetration of HiSeq X Ten, Maxim Group said.

Eli Lilly (LLY) was downgraded at Leerink Swann to neutral from buy. Twelve-month price target is $61. Company lacks near-term catalysts and made an expensive acquisition of Novartis' animal health business, Leerink Swann said.

Quality Systems (QSII) was downgraded at Morgan Stanley to underweight from equal-weight. Twelve-month price target is $15. Company will be hurt from consolidation of its customer base, Morgan Stanley said.

Must Read: Analysts' Actions: ATHN CMG DYN CSOD YUM

Nacco (NC) was upgraded to hold at TheStreet Ratings.

Rexnord (RXN) was downgraded at Bank of America/Merrill Lynch to underperform. Valuation call, based on a 12-month price target of $29, Bank of America/Merrill said.

Sunpower (SPWR) was upgraded at Bank of America/Merrill Lynch to buy. Valuation call, based on a 12-month price target of $37, Bank of America/Merrill said.

TECO Energy (TE) was upgraded at UBS to neutral from sell. Driven by group recovery, deal savings and better coal outlook, UBS said. Twelve-month price target is $17.

UGI (UGI) was initiated with an equal weight rating at Barclays. LOB generates excess cash flow, with estimated growth earnings at around 6% CAGR, Barclays said. Twelve-month price target is $47.

Vitamin Shoppe (VSI) was upgraded to buy at Sterne Agee. Twelve-month price target is $57. Same-store sales and margins appear to be at an inflection point, Sterne Agee said.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AOS $72.76 -0.84%
ETFC $29.92 -0.78%
AAPL $126.44 -0.13%
FB $87.28 0.43%
GOOG $523.40 0.30%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs